THTX – Theratechnologies Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 6.05

Low: 3

High: 9

Total Analysts: 2

Company Profile

Theratechnologies Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. The Company commercializes two medicines in human immunodeficiency viruses (HIV) and has research programs in non-alcoholic steatohepatitis (NASH), Oncology and HIV. Its medicines include Trogarzo, EGRIFTA SV, and EGRIFTA. Trogarzo (ibalizumab-uiyk) is a monoclonal antibody which binds to domain 2 of the cluster difference 4 (CD4) T cell receptors. In the United States, Trogarzo is developed for the treatment of HIV-1 infection. EGRIFTA SV (tesamorelin for injection) and EGRIFTA are developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Its oncology pipeline includes TH1902 and TH1904. Its Non-alcoholic fatty liver disease (NAFLD) pipeline includes Tesamorelin F8. TH1902 is being evaluated in a Phase I clinical trial.

We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan